Progyny (NASDAQ:PGNY – Get Rating) updated its FY 2022 earnings guidance on Monday. The company provided EPS guidance of $0.07-$0.14 for the period, compared to the consensus EPS estimate of $0.12. The company issued revenue guidance of $735.00 million-$775.00 million, compared to the consensus revenue estimate of $754.06 million.Progyny also updated its Q2 2022 guidance to $0.01-$0.02 EPS.
A number of research analysts have issued reports on PGNY shares. Zacks Investment Research raised Progyny from a hold rating to a buy rating and set a $38.00 target price for the company in a research note on Thursday, May 12th. TheStreet cut Progyny from a c- rating to a d+ rating in a research note on Friday, January 28th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Progyny currently has an average rating of Buy and a consensus price target of $65.86.
Shares of PGNY stock traded down $0.98 on Monday, hitting $34.20. 24,421 shares of the stock were exchanged, compared to its average volume of 702,828. The firm has a market capitalization of $3.14 billion, a P/E ratio of 62.82, a price-to-earnings-growth ratio of 17.58 and a beta of 2.01. The business has a 50-day moving average of $42.83 and a 200 day moving average of $45.46. Progyny has a fifty-two week low of $32.06 and a fifty-two week high of $68.32.
In related news, CEO Peter Anevski sold 21,000 shares of the company’s stock in a transaction dated Wednesday, March 2nd. The stock was sold at an average price of $44.02, for a total transaction of $924,420.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Norman Payson sold 8,330 shares of the company’s stock in a transaction dated Wednesday, February 23rd. The stock was sold at an average price of $35.30, for a total value of $294,049.00. The disclosure for this sale can be found here. Insiders have sold 514,485 shares of company stock valued at $21,912,831 over the last ninety days. 14.00% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in PGNY. Lazard Asset Management LLC bought a new stake in Progyny during the first quarter worth about $62,000. Parkside Financial Bank & Trust bought a new stake in Progyny in the first quarter valued at approximately $70,000. Captrust Financial Advisors raised its stake in Progyny by 25.0% in the first quarter. Captrust Financial Advisors now owns 2,091 shares of the company’s stock valued at $107,000 after buying an additional 418 shares during the period. Mackenzie Financial Corp bought a new stake in Progyny in the first quarter valued at approximately $216,000. Finally, Cetera Investment Advisers raised its stake in Progyny by 4.4% in the fourth quarter. Cetera Investment Advisers now owns 6,359 shares of the company’s stock valued at $320,000 after buying an additional 270 shares during the period. Institutional investors and hedge funds own 82.51% of the company’s stock.
About Progyny (Get Rating)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- Time to Ring the Register on Funko Stock
- Under Armor Stock is Getting Undervalued
- Stock Market Downgrades Are Dragging The S&P 500 Lower
- Palo Alto Networks Bottoms But A Rebound May Not Be Coming
- The Institutions Go Long Saia, Inc In Q2
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.